Enhanced cardioprotection against ischemia-reperfusion injury with a dipyridamole and low-dose atorvastatin combination

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 293, Issue 1, 2007, Pages

  Ye, Yumei ^a   Lin, Yu ^a   Perez Polo, Regino ^a   Huang, Ming He ^a   Hughes, Michael G ^a   McAdoo, David J ^a   Manickavasagam, Saraswathy ^a   Uretsky, Barry F ^a   Birnbaum, Yochai ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

Author keywords

Adenosine; Akt; Infarct size; Nitric oxide synthase

Indexed keywords

ADENOSINE; AMINOPHYLLINE; ATORVASTATIN; DIPYRIDAMOLE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; SERINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVATION; HEART MUSCLE ISCHEMIA; HEART PERFUSION; HEART PROTECTION; IMMUNOBLOTTING; LOW DRUG DOSE; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; REPERFUSION INJURY; TREATMENT OUTCOME;

ADENOSINE; ADMINISTRATION, ORAL; ANIMALS; CARDIOTONIC AGENTS; DIPYRIDAMOLE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; DRUG SYNERGISM; HEPTANOIC ACIDS; MALE; MYOCARDIAL REPERFUSION INJURY; PYRROLES; RATS; RATS, SPRAGUE-DAWLEY; TREATMENT OUTCOME;

EID: 34447499108     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00210.2007     Document Type: Article

References (54)

1. Ali Raza J, Reeves WC, Movahed A. Pharmacological stress agents for evaluation of ischemic heart disease. Int J Cardiol 81: 157-167, 2001.
2. Amin-Hanjani S, Stagliano NE, Yamada M, Huang PL, Liao JK, Moskowitz MA. Mevastatin, an HMG-CoA reductase inhibitor, reduces stroke damage and upregulates endothelial nitric oxide synthase in mice. Stroke 32: 980-986, 2001.
3. Atar S, Ye Y, Lin Y, Freeberg SY, Nishi SP, Rosanio S, Huang MH, Uretsky BF, Perez-Polo JR, Birnbaum Y. Atorvastatin-induced cardio-protection is mediated by increasing inducible nitric oxide synthase and consequent S-nitrosylation of cyclooxygenase-2. Am J Physiol Heart Circ Physiol 290: H1960-H1968, 2006.
4. ATP channels, and ischemic preconditioning in dogs. Am J Physiol Heart Circ Physiol 264: H1327-H1336, 1993.
5. Bell RM, Yellon DM. Atorvastatin, administered at the onset of reperfusion, and independent of lipid lowering, protects the myocardium by up-regulating a pro-survival pathway. J Am Coll Cardiol 41: 508-515, 2003.
6. Birnbaum Y, Ashitkov T, Uretsky BF, Ballinger S, Motamedi M. Reduction of infarct size by short-term pretreatment with atorvastatin. Cardiovasc Drugs Ther 17: 25-30, 2003.
7. Birnbaum Y, Lin Y, Ye Y, Martinez JD, Huang MH, Lui CY, Perez-Polo JR, Uretsky BF. Aspirin before reperfusion blunts the infarct size limiting effect of atorvastatin. Am J Physiol Heart Circ Physiol 292: H2891-H2897, 2007.
8. Birnbaum Y, Ye Y, Lin Y, Freeberg SY, Nishi SP, Martinez JD, Huang MH, Uretsky BF, Perez-Polo JR. Augmentation of myocardial production of 15-epi-lipoxin-a4 by pioglitazone and atorvastatin in the rat. Circulation 114: 929-935, 2006.
9. Birnbaum Y, Ye Y, Lin Y, Uretsky BF, Kitakaze M, Perez-Polo JR. Mechanisms of myocardial protection by atorvastatin: 5′-nucleotidase is upstream to eNOS activation (Abstract). Circ Res 99: E26, 2006.
10. Birnbaum Y, Ye Y, Rosanio S, Tavackoli S, Hu ZY, Schwarz ER, Uretsky BF. Prostaglandins mediate the cardioprotective effects of atorvastatin against ischemia-reperfusion injury. Cardiovasc Res 65: 345-355, 2005.
11. Brouet A, Sonveaux P, Dessy C, Moniotte S, Balligand JL, Feron O. Hsp90 and caveolin are key targets for the proangiogenic nitric oxide-mediated effects of statins. Circ Res 89: 866-873, 2001.
12. Efthymiou CA, Mocanu MM, Yellon DM. Atorvastatin and myocardial reperfusion injury: new pleiotropic effect implicating multiple prosurvival signaling. J Cardiovasc Pharmacol 45: 247-252, 2005.
13. Endres M, Laufs U, Huang Z, Nakamura T, Huang P, Moskowitz MA, Liao JK. Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc Natl Acad Sci USA 95: 8880-8885, 1998.
14. Figueredo VM, Diamond I, Zhou HZ, Camacho SA. Chronic dipyridamole therapy produces sustained protection against cardiac ischemiareperfusion injury. Am J Physiol Heart Circ Physiol 277: H2091-H2097, 1999.
15. Gao F, Christopher TA, Lopez BL, Friedman E, Cai G, Ma XL. Mechanism of decreased adenosine protection in reperfusion injury of aging rats. Am J Physiol Heart Circ Physiol 279: H329-H338, 2000.
16. Gross ER, Gross GJ. Ligand triggers of classical preconditioning and postconditioning. Cardiovasc Res 70: 212-221, 2006.
17. Harker LA, Kadatz RA. Mechanism of action of dipyridamole. Thromb Res Suppl 4: 39-46, 1983.
18. Harris MB, Blackstone MA, Sood SG, Li C, Goolsby JM, Venema VJ, Kemp BE, Venema RC. Acute activation and phosphorylation of endothelial nitric oxide synthase by HMG-CoA reductase inhibitors. Am J Physiol Heart Circ Physiol 287: H560-H566, 2004.
19. Hausenloy DJ, Yellon DM. New directions for protecting the heart against ischaemia-reperfusion injury: targeting the reperfusion injury salvage kinase (RISK)-pathway. Cardiovasc Res 61: 448-460, 2004.
20. Heidland UE, Heintzen MP, Michel CJ, Strauer BE. Intracoronary administration of dipyridamole prior to percutaneous transluminal coronary angioplasty provides a protective effect exceeding that of ischemic preconditioning. Coron Artery Dis 11: 607-613, 2000.
21. Heidland UE, Heintzen MP, Schwartzkopff B, Strauer BE. Preconditioning during percutaneous transluminal coronary angioplasty by endogenous and exogenous adenosine. Am Heart J 140: 813-820, 2000.
22. Itoya M, Miura T, Sakamoto J, Urabe K, Iimura O. Nucleoside transport inhibitors enhance the infarct size-limiting effect of ischemic preconditioning. J Cardiovasc Pharmacol 24: 846-852, 1994.
23. Jones S, Gibson M, Rimmer D, Gibson T, Sharp B, Lefer D. Direct vascular and cardioprotective effects of rosuvastatin, a new HMG-CoA reductase inhibitor. J Am Coll Cardiol 40: 1172-1178, 2002.
24. Jones SP, Trocha SD, Lefer DJ. Pretreatment with simvastatin attenuates myocardial dysfunction after ischemia and chronic reperfusion. Arterioscler Thromb Vasc Biol 21: 2059-2064, 2001.
25. Kitakaze M, Minamino T, Node K, Koretsune Y, Komamura K, Funaya H, Kuzuya T, Hori M. Elevation of plasma adenosine levels may attenuate the severity of chronic heart failure. Cardiovasc Drugs Ther 12: 307-309, 1998.
26. Krieg T, Qin Q, McIntosh EC, Cohen MV, Downey JM. ACh and adenosine activate PI3-kinase in rabbit hearts through transactivation of receptor tyrosine kinases. Am J Physiol Heart Circ Physiol 283: H2322-H2330, 2002.
27. Kureishi Y, Luo Z, Shiojima I, Bialik A, Fulton D, Lefer DJ, Sessa WC, Walsh K. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med 6: 1004-1010, 2000.
28. Lee TM, Su SF, Chou TF, Tsai CH. Effect of pravastatin on myocardial protection during coronary angioplasty and the role of adenosine. Am J Cardiol 88: 1108-1113, 2001.
29. 2a receptors increase arterial endothelial cell nitric oxide. J Surg Res 80: 357-364, 1998.
30. Mensah K, Mocanu MM, Yellon DM. Failure to protect the myocardium against ischemia/reperfusion injury after chronic atorvastatin treatment is recaptured by acute atorvastatin treatment: a potential role for phosphatase and tensin homolog deleted on chromosome ten? J Am Coll Cardiol 45: 1287-1291, 2005.
31. Miura T, Ogawa T, Iwamoto T, Shimamoto K, Iimura O. Dipyridamole potentiates the myocardial infarct size-limiting effect of ischemic preconditioning. Circulation 86: 979-985, 1992.
32. Pasini FL, Guideri F, Ferber D, Galgano G, Bianchi A, Isidori S, De Giorgi L, Petri S, Capecchi PL, Di Perri T. Pharmacological preconditioning of ischemic heart disease by low-dose dipyridamole. Int J Cardiol 56: 17-27, 1996.
33. Riksen NP, Oyen WJ, Ramakers BP, Van den Broek PH, Engbersen R, Boerman OC, Smits P, Rongen GA. Oral therapy with dipyridamole limits ischemia-reperfusion injury in humans. Clin Pharmacol Ther 78: 52-59, 2005.
34. Rosanio S, Ye Y, Atar S, Rahman AM, Freeberg SY, Huang MH, Uretsky BF, Birnbaum Y. Enhanced cardioprotection against ischemia-reperfusion injury with combining sildenafil with low-dose atorvastatin. Cardiovasc Drugs Ther 20: 27-36, 2006.
35. Sanada S, Asanuma H, Minamino T, Node K, Takashima S, Okuda H, Shinozaki Y, Ogai A, Fujita M, Hirata A, Kim J, Asano Y, Mori H, Tomoike H, Kitamura S, Hori M, Kitakaze M. Optimal windows of statin use for immediate infarct limitation: 5′-nucleotidase as another downstream molecule of phosphatidylinositol 3-kinase. Circulation 110: 2143-2149, 2004.
36. Scalia R, Gooszen ME, Jones SP, Hoffmeyer M, Rimmer DM, 3rd Trocha SD, Huang PL, Smith MB, Lefer AM, Lefer DJ. Simvastatin exerts both anti-inflammatory and cardioprotective effects in apolipoprotein E-deficient mice. Circulation 103: 2598-2603, 2001.
37. Schaper W. Dipyridamole, an underestimated vascular protective drug. Cardiovasc Drugs Ther 19: 357-363, 2005.
38. Skaletz-Rorowski A, Lutchman M, Kureishi Y, Lefer DJ, Faust JR, Walsh K. HMG-CoA reductase inhibitors promote cholesterol-dependent Akt/PKB translocation to membrane domains in endothelial cells. Cardiovasc Res 57: 253-264, 2003.
39. Smits P, Williams SB, Lipson DE, Banitt P, Rongen GA, Creager MA. Endothelial release of nitric oxide contributes to the vasodilator effect of adenosine in humans. Circulation 92: 2135-2141, 1995.
40. 2-purinoceptors by adenosine stimulates L-arginine transport (system y+) and nitric oxide synthesis in human fetal endothelial cells. J Physiol 499: 135-140, 1997.
41. Strauer BE, Heidland UE, Heintzen MP, Schwartzkopff B. Pharmacologic myocardial protection during percutaneous transluminal coronary angioplasty by intracoronary application of dipyridamole: impact on hemodynamic function and left ventricular performance. J Am Coll Cardiol 28: 1119-1126, 1996.
42. Suzuki K, Miura T, Miki T, Tsuchida A, Shimamoto K. Infarct-size limitation by preconditioning is enhanced by dipyridamole administered before but not after preconditioning: evidence for the role of interstitial adenosine level during preconditioning as a primary determinant of cardioprotection. J Cardiovasc Pharmacol 31: 1-9, 1998.
43. + channels. Coron Artery Dis 15: 53-58, 2004.
44. Tiefenbacher CP, Kapitza J, Dietz V, Lee CH, Niroomand F. Reduction of myocardial infarct size by fluvastatin. Am J Physiol Heart Circ Physiol 285: H59-H64, 2003.
45. Todosiichuk VV, Kuznetsov VA. Effect of dipyridamole on the phenomenon of ischemic preconditioning in patients with ischemic heart disease during paired bicycle ergometer tests. [In Russian.] Kardiologiia 45: 23-25, 2005.
46. Ueda Y, Kitakaze M, Komamura K, Minamino T, Asanuma H, Sato H, Kuzuya T, Takeda H, Hori M. Pravastatin restored the infarct size-limiting effect of ischemic preconditioning blunted by hypercholesterolemia in the rabbit model of myocardial infarction. J Am Coll Cardiol 34: 2120-2125, 1999.
47. 2-purinoceptor-mediated relaxation in the guinea-pig coronary vasculature: a role for nitric oxide. Br J Pharmacol 109: 424-429, 1993.
48. Wayman NS, Ellis BL, Thiemermann C. Simvastatin reduces infarct size in a model of acute myocardial ischemia and reperfusion in the rat. Med Sci Monit 9: BR155-BR159, 2003.
49. Wojcik WJ, Neff NH. Adenosine measurement by a rapid HPLC-fluorometric method: induced changes of adenosine content in regions of rat brain. J Neurochem 39: 280-282, 1982.
50. Wolfrum S, Dendorfer A, Schutt M, Weidtmann B, Heep A, Tempel K, Klein HH, Dominiak P, Richardt G. Simvastatin acutely reduces myocardial reperfusion injury in vivo by activating the phosphatidylinositide 3-kinase/Akt pathway. J Cardiovasc Pharmacol 44: 348-355, 2004.
51. Wolfrum S, Grimm M, Heidbreder M, Dendorfer A, Katus HA, Liao JK, Richardt G. Acute reduction of myocardial infarct size by a hydroxymethyl glutaryl coenzyme A reductase inhibitor is mediated by endothelial nitric oxide synthase. J Cardiovasc Pharmacol 41: 474-480, 2003.
52. Yamakuchi M, Greer JJ, Cameron SJ, Matsushita K, Morrell CN, Talbot-Fox K, Baldwin WM 3rd, Lefer DJ, Lowenstein CJ. HMG-CoA reductase inhibitors inhibit endothelial exocytosis and decrease myocardial infarct size. Circ Res 96: 1185-1192, 2005.
53. Ye Y, Lin Y, Atar S, Huang MH, Perez-Polo JR, Uretsky BF, Birnbaum Y. Myocardial protection by pioglitazone, atorvastatin, and their combination: mechanisms and possible interactions. Am J Physiol Heart Circ Physiol 291: H1158-H1169, 2006.
54. Ye Y, Ramanna M, Lin Y, Martinez JD, Uretsky BF, Perez-Polo JR, Birnbaum Y. The role of adenosine in activation of endothelial nitric oxide synthase (eNOS) by atorvastatin: adenosine, generated by ecto-5′- nucleotidase, is needed for Akt phosphorylation by phosphorylated 3-phosphoinositide-dependent kinase 1 (PDK1) (Abstract). J Am Col Cardiol Suppl A 49: 184A, 2007.